Featured Research

from universities, journals, and other organizations

New approach may help dialysis patients fight anemia

Date:
November 30, 2010
Source:
American Society of Nephrology
Summary:
A new drug called FG-2216 can stimulate production of the hormone erythropoietin in dialysis patients -- possibly offering a new approach to treatment of kidney disease-related anemia, according to a new study.

A new drug called FG-2216 can stimulate production of the hormone erythropoietin (EPO) in dialysis patients -- possibly offering a new approach to treatment of kidney disease-related anemia, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

Anemia is a major problem in patients with kidney disease. It is caused by low production of EPO, which has been assumed to result from damage to the kidney cells that produce EPO. "Our study clearly shows that this may not be the case, and that the kidneys of patients on dialysis retain significant ability to produce erythropoietin," comments Wanja M. Bernhardt, MD (Department of Nephrology, University hospital Erlangen, Germany). "Renal anemia seems to result from disturbed regulation rather than lost production capacity of the hormone."

The study evaluated an experimental drug called FG-2216. FG-2216 is a prolyl-hydroxylase inhibitor that stabilizes hypoxia-inducible transcription factor (HIF) -- the "master switch" that normally tells the body to produce EPO in response to low oxygen levels. EPO stimulates production of oxygen-carrying red blood cells.

Treatment with FG-2216 significantly increased EPO production in dialysis patients, as well as in healthy people with normal kidneys. The greatest increase in EPO production occurred in dialysis patients whose kidneys were still present, but no longer functioning.

FG-2216 also stimulated EPO production in dialysis patients who had no kidneys. (Their kidneys had been removed at surgery for cancer or other diseases.) The increase in EPO production in patients without kidneys was almost as high as in people with normally functioning kidneys. In the patients without kidneys, FG-2216 apparently stimulated production of EPO by the liver.

Take-home message: The results question the conventional wisdom that dialysis-related anemia occurs because patients with advanced kidney disease can no longer make their own EPO. "Our results confirm that both the liver and the kidneys retain a significant production capacity for erythropoietin in end-stage renal disease patients," says Bernhardt.

Currently, patients with dialysis-related anemia receive EPO replacement therapy with drugs called erythropoiesis-stimulating agents (ESAs). Despite almost two decades of use, there remains an ongoing controversy related to the safety, appropriate clinical use, and in particular high costs of ESAs. If the new results are borne out by future studies, then using prolyl-hydroxylase inhibitor such as FG-2216 to help the body make its own EPO might provide a new alternative to ESAs.

The preliminary study evaluated only the response to a single dose of FG-2216. Although there were no adverse effects, the results and long-term safety of activation of HIF by prolyl-hydroxylase inhibitors remain unclear. Further study will also be needed to find out why HIF is apparently not stabilized in response to decreased oxygen concentrations in patients with kidney disease but responds to treatment with prolyl-hydroxylase inhibitors.

Study co-authors include James Chou, Kai-Uwe Eckardt, Volkmar Gunzler, Roland Schmieder, Paul Scigalla, and Michael Wiesener.


Story Source:

The above story is based on materials provided by American Society of Nephrology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Inhibition of Prolyl Hydroxylases Increases Erythropoietin Production in ESRD. Journal of the American Society of Nephrology, November 29, 2010 DOI: 10.1681/ASN.2010010116

Cite This Page:

American Society of Nephrology. "New approach may help dialysis patients fight anemia." ScienceDaily. ScienceDaily, 30 November 2010. <www.sciencedaily.com/releases/2010/11/101129203326.htm>.
American Society of Nephrology. (2010, November 30). New approach may help dialysis patients fight anemia. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2010/11/101129203326.htm
American Society of Nephrology. "New approach may help dialysis patients fight anemia." ScienceDaily. www.sciencedaily.com/releases/2010/11/101129203326.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins